COURT-RULING ·Filed Jul 13, 2026

TMCI

TREACE MEDICAL CONCEPTS, INC.
BEARISH
Impact 5/10
Horizonmonths Processed2mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight ▼ Bearish

The dismissal of antitrust claims is a setback but not fatal; the patent infringement case continues. Treace may amend its antitrust claims, but the court's skepticism on antitrust injury is a headwind. Monitor for any amended complaint or developments in the patent case.

DirectionBearish
Confidencehigh
Horizonmonths
Latest settled — T+20d
TMCI ▲ +1.97% at T+20d
SHORT call ✗ call lost -1.97% · α vs SPY +1.22% · entry $4.58 → $4.67
Next anchor: T+60d in 3d
Latest observation: T+56 +58.42% FF3 residual α
Entry anchored
Jul 10, 03:59 PM ET
via exchange tick
T+1d
-3.06%
call +3.06% · α +3.41%
$4.44
settled 3mo ago
T+5d
-6.11%
call +6.11% · α +5.33%
$4.30
settled 3mo ago
T+20d
+1.97%
call -1.97% · α +1.22%
$4.67
settled 8w ago
T+60d
—
call — · α —
—
in 3d

Price Chart

Loading chart...

Executive Summary

The District of New Jersey granted Stryker's motion to dismiss Treace's antitrust (Sherman Act, Clayton Act, state antitrust) and tortious interference claims without prejudice, finding Treace failed to plead antitrust injury. The patent infringement claims (Counts I-XII) survive. The ruling removes a potential avenue for broad relief but does not end the litigation.

Court Ruling Details

Ruling Date
Jul 13, 2026
Court
United States District Court District of New Jersey
Court Level
District
Judge
Jamel K. Semper
Case Type
antitrust
Ruling Type
motion to dismiss
Outcome
LOSS — ruling against this company
Will It Be Appealed?
Unlikely
Precedent Risk
LOW

Key Facts

  • Court granted motion to dismiss Counts XIII–XVI (antitrust and tortious interference) without prejudice.
  • Treace failed to plead antitrust injury — allegations were conclusory and only alleged harm to itself, not to competition in the TMT Bunion Systems Market.
  • Patent infringement claims (Counts I–XII) remain pending.
  • Treace may file a second amended complaint to attempt to cure the pleading deficiencies.

Financial Impact

No monetary relief ordered; dismissal without prejudice preserves ability to replead. Patent case continues with no immediate financial impact.

Risk Factors

  • Treace may fail to adequately replead antitrust injury, leading to dismissal with prejudice.
  • Patent case carries its own risks — Stryker may seek invalidity or non-infringement rulings.
  • Litigation costs and management distraction could pressure the small-cap stock.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
10% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-889e1f0a26-TMCI
6 reports for TMCI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TMCI — sortable, filterable
TypeNow
Aug 7, 2026
8w ago
8-K
MIXED ★ 6/10
$4.76 $4.81▲ +1.05%▲ +1.45%$4.39 (−7.77%)
Jul 13, 2026
11w ago
Court Ruling
BEARISH ★ 5/10
$4.58 $4.67▼ −1.97%▲ +1.22%$4.39 (+4.15%)
May 8, 2026
21w ago
Press Release
BEARISH ★ 7/10
$2.01 $3.51▼ −74.63%▼ −74.60%$4.39 (−118.41%)
Apr 24, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$1.98 $2.84▲ +43.43%▲ +39.41%$4.39 (+121.72%)
Apr 9, 2026
25w ago
8-K
MIXED ★ 6/10
$1.53 $1.93▲ +26.14%▲ +18.58%$4.39 (+186.93%)
Apr 6, 2026
25w ago
DEFA14A
NEUTRAL ★ 2/10
$1.44 $1.83▲ +27.08%▲ +18.10%$4.39 (+204.86%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (38h 29m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access